SeekingAlphaOctober 5, 2026 at 11:37 PM NY22 Days Ago
Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade)
Arcutis Biotherapeutics' fair value is estimated at $24.41 per share, with upside contingent on clinical wins. Read why ARQT stock is downgraded to a hold.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha
